Category Archive: tuberculosis

Jul
16

What’s needed for TB: A critical analysis of the drug discovery pipeline and efforts

After attending the Gordon conference on Tuberculosis (TB) drug discovery (without breaking the rules on describing what was presented) I think I can safely make a few general comments which were already in my mind before the meeting. This week what stood out for me was the lack of knowledge of all the efforts that …

Continue reading »

Jul
13

Waging war on infectious diseases

While I am at the Gordon Conference on Tuberculosis (TB) Drug Discovery and Development this week I cannot live Tweet due to their policy. I do however have some thoughts based on my observations. This is not a war fought by soldiers armed with guns and artillery against an enemy similarly armed, this is a …

Continue reading »

Jul
09

Observations on big and small collaborations

Its been a pretty hectic year to date with several grants coming to their conclusion and the need for writing up final reports and manuscripts. In addition it has provided just a little time for reflection. Pretty much everything I am involved in is a collaboration of some sort so I am just a tiny …

Continue reading »

Jun
10

The Case for Why the EC Needs to Fund Small Molecule TB Drug Discovery

My previous post may have been too refined..so let me revert to a drier scientific style. In the last few weeks Iain Old, Giovanna Riccardi, myself and several others from the MM4TB project have been lobbying MEPs and basically anyone who will listen to try to raise awareness of the lack of funding for TB …

Continue reading »

Jun
05

The war against Tuberculosis needs new drugs

This is not a call to arms for a war fought with bombs and bullets, but one which is equally catastrophic in terms of human loss. We are fighting armies of microscopic bacteria called Tuberculosis (TB) that knows no country boundaries, infecting 9 million and killing 1.5 million per year. Human kind has only defended …

Continue reading »

May
12

Papers and posters for ACS Boston 2015

It is that time of the year when we get those automated emails telling us our abstracts have been scheduled for the next ACS in August. In addition to these I will be participating in a careers panel for undergraduates which will be interesting – hopefully to inspire the next generation that there is lots …

Continue reading »

May
01

The next generation of Tuberculosis researchers

I like to help and mentor students in various ways when I can. Over the years this has lead to some fun projects and computational models. For a long time I have been an Adjunct Associate Professor at the University of Maryland, yet today I heard about a group of undergraduates there working on Tuberculosis. …

Continue reading »

Dec
15

A year in publications – 2014

A year in collaborative publications, the ups and downs and a few random comments as well (with a big thanks to all involved): 1. Ekins S and Freundlich JS and Coffee M, A common feature pharmacophore for FDA-approved drugs inhibiting the Ebola virus, F1000research, 3: 277, 2014. This came initially from a Twitter exchange of …

Continue reading »

Oct
16

How the experiment may impact the data

Here’s one to file under “I am still trying to get my head around it”. Back in April at the CDD community meeting Christopher (Chris) Lipinski presented some slides looking at kinase selectivity and the relationship with ligand efficiency. There seemed to be a general trend that more selective compounds had a better ligand efficiency. …

Continue reading »

Oct
08

Where is the big Pharma Knight riding in to slay Ebola?

In full disclosure my better half works for a big pharma, this is not going to hold me back from writing what I am sure everyone is thinking. It saddens me as someone who worked for big pharma (until 2001) to have to write this. We are months into the rapidly escalating catastrophe that is …

Continue reading »

Older posts «

» Newer posts